Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming

[1]  R. Sinden,et al.  Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I‐restricted epitope with recombinant carriers suitable for human use , 1998, European journal of immunology.

[2]  Marion Becker,et al.  Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara , 1998, Nature Medicine.

[3]  P. Allen,et al.  Inhibition of an in vitro CD4+ T cell alloresponse using altered peptide ligands. , 1998, Journal of immunology.

[4]  D. Kwiatkowski,et al.  Association of malaria parasite population structure, HLA, and immunological antagonism. , 1998, Science.

[5]  A. Hill,et al.  A protein particle vaccine containing multiple malaria epitopes , 1997, Nature Biotechnology.

[6]  H. Yagita,et al.  Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope , 1997, European journal of immunology.

[7]  A. Hill,et al.  Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa. , 1997, Journal of immunology.

[8]  Partho Ghosh,et al.  Structure of the complex between human T-cell receptor, viral peptide and HLA-A2 , 1996, Nature.

[9]  V. Apostolopoulos,et al.  Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. , 1996, Vaccine.

[10]  M. Nowak,et al.  Population Dynamics of Immune Responses to Persistent Viruses , 1996, Science.

[11]  P. Allen,et al.  Endogenous altered peptide ligands can affect peripheral T cell responses , 1996, The Journal of experimental medicine.

[12]  S. Hoffman,et al.  Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity , 1996, The Journal of experimental medicine.

[13]  D I Stuart,et al.  An altered position of the alpha 2 helix of MHC class I is revealed by the crystal structure of HLA-B*3501. , 1996, Immunity.

[14]  A. Sette,et al.  Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon gamma by T cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Sunetra Gupta,et al.  Dynamic interactions in malaria: host heterogeneity meets parasite polymorphism , 1995, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[16]  M. Davenport,et al.  Antagonists or altruists: do viral mutants modulate T-cell responses? , 1995, Immunology today.

[17]  P. Klenerman,et al.  The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus , 1995, European journal of immunology.

[18]  H. Grey,et al.  MHC blocking peptides and T-cell receptor antagonists: novel paths to selective immunosuppression? , 1995, Chemical immunology.

[19]  Martin A. Nowak,et al.  Antigenic oscillations and shifting immunodominance in HIV-1 infections , 1995, Nature.

[20]  M. Aidoo,et al.  Induction of peptide‐specific primary cytotoxic T lymphocyte responses from human peripheral blood , 1995, European journal of immunology.

[21]  A. Sette,et al.  Differential activation of proliferation and cytotoxicity in human T-cell lymphotropic virus type I Tax-specific CD8 T cells by an altered peptide ligand. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Hill,et al.  Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria , 1995, The Lancet.

[23]  A. Sette,et al.  Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo , 1995, The Journal of experimental medicine.

[24]  A. Sette,et al.  Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. , 1995, Immunity.

[25]  D. Mitchell,et al.  Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production , 1994, The Journal of experimental medicine.

[26]  J. Levy,et al.  Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein , 1994, The Journal of experimental medicine.

[27]  A. Sette,et al.  Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells , 1994, Nature.

[28]  Sarah Rowland-Jones,et al.  Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants , 1994, Nature.

[29]  H. Grey,et al.  Negative selection of CD4+ CD8+ thymocytes by T-cell receptor peptide antagonists. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Bevan,et al.  Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells , 1993, The Journal of experimental medicine.

[31]  P. Allen,et al.  Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells , 1993, Nature.

[32]  J. Bell,et al.  Characterization of the human T cell receptor α‐chain repertoire and demonstration of a genetic influence on Vα usage , 1993, European journal of immunology.

[33]  P. Allen,et al.  Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides. , 1993, Journal of immunology.

[34]  M. Aidoo,et al.  Molecular analysis of the association of HLA-B53 and resistance to severe malaria , 1992, Nature.

[35]  Charles R. M. Bangham,et al.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition , 1991, Nature.

[36]  P. Allen,et al.  Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. , 1991, Science.

[37]  V. Nussenzweig,et al.  Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria , 1989, Nature.

[38]  S. Hoffman,et al.  Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. , 1989, Science.

[39]  J. Rothbard,et al.  Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein , 1988, Cell.

[40]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[41]  J Alexander,et al.  Antigen analogs/MHC complexes as specific T cell receptor antagonists. , 1994, Annual review of immunology.

[42]  E. Nardin,et al.  T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. , 1993, Annual review of immunology.